Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
BIIB
BuyFLAGBiogen Inc. · Healthcare · United States · $32.2B · Avg Vol: $191M/d
Biogen screens cheap with strong momentum (M77), but the quality score is weak (Q60) and the core issue is nameable: its legacy multiple sclerosis franchise is in structural decline while the Alzheimer's launch has been slow to scale against reimbursement and diagnostic-infrastructure friction. That revenue-replacement gap is the dominant variable. No accounting or solvency issue is known, so this is a flag.
COMPANY DESCRIPTION
Biogen Inc. is a global biotechnology company focused on discovering, developing, manufacturing, and delivering innovative therapies for people living with serious neurological and neurodegenerative diseases. The company holds a leading market position in multiple sclerosis treatments and is a pioneer in Alzheimer's disease research, backed by a robust R&D pipeline. Its specialized focus on neuroscience provides a distinct competitive advantage and addresses significant unmet medical needs.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 10.2B | 9.8B | 9.7B | 9.9B | -0.9% | 10.0B | 10.4B | 10.7B | 3.8% |
| EPS | 20.96 | 8.02 | 11.21 | 8.83 | -25.0% | 5.63 | 7.17 | 9.56 | 4.0% |
| Shares | 144.0M | 144.9M | 145.7M | 146.8M | +1.9% | 147.8M | — | — | — |
| Debt | 6.6B | 7.3B | 6.6B | 6.6B | -0.2% | 8.4B | — | — | — |
| Equity | 13.4B | 14.8B | 16.7B | 18.3B | 10.9% | — | — | — | — |
| Op CF | 1.4B | 1.5B | 2.9B | 2.2B | 16.8% | 2.9B | — | — | — |
| Inv CF | 1.6B | -4.1B | -799.2M | -1.4B | — | — | — | — | — |
| Fin CF | -1.7B | 149.3M | -683.5M | -301.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of BIIB are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| BIIB | Biogen Inc.(you) | $32.2B | 78 | Buy |
| GILD | Gilead Sciences, Inc. | $182.0B | 76 | Buy |
| PFE.DE | Pfizer Inc. | $158.9B | 88 | Strong Buy |
| BMY | Bristol-Myers Squibb Company | $137.4B | 99 | Strong Buy |
| MRCK34.SA | Merck & Co., Inc. | $384.9B | 79 | Buy |
| AMGN | Amgen Inc. | $240.0B | 89 | Strong Buy |
| OGN | Organon & Co. | $3.6B | 95 | Strong Buy |
| JNJ.DE | Johnson & Johnson | $651.4B | 80 | Strong Buy |
| ABBV | AbbVie Inc. | $467.4B | 87 | Strong Buy |
| LLY | Eli Lilly and Company | $1.1T | 77 | Buy |
Peer medians: ROE -25.8% · P/E 29.5x · Gross margin 58.7%